8-KLeadership ChangesCorporate ChangesExhibits & Filings

ALTRIA GROUP, INC. 8-K Report, Executive Changes (Oct 28, 2008)

Filed October 28, 2008For Securities:MO

Summary

Altria Group, Inc. (MO) filed a Form 8-K on October 28, 2008, reporting key changes to its Board of Directors and corporate governance. The company appointed Dr. Nabil Y. Sakkab as a new director, filling a newly created position on the Board and its Innovation Committee. Dr. Sakkab's appointment strengthens the board's expertise, particularly in innovation, and he has been determined to meet independent director standards. In conjunction with this appointment, Altria also amended its By-laws to increase the size of its Board of Directors from eight to nine members. These changes are effective immediately and signify a move to enhance board oversight and strategic direction, with a particular focus on innovation initiatives. The filing includes the press release announcing Dr. Sakkab's appointment and the amended By-laws as exhibits.

Key Highlights

  • 1Appointment of Dr. Nabil Y. Sakkab to the Board of Directors.
  • 2Creation of a new Innovation Committee on the Board of Directors.
  • 3Dr. Sakkab has been deemed an independent director by Altria and the NYSE.
  • 4The size of Altria's Board of Directors has been increased from eight to nine members.
  • 5The company amended its Amended and Restated By-laws to reflect the board size increase.
  • 6These changes were effective as of October 28, 2008.

Frequently Asked Questions

Dr. Nabil Y. Sakkab has been appointed as a new director to Altria Group, Inc.'s Board of Directors. He will also serve on the newly established Innovation Committee of the Board, bringing his expertise to guide the company's innovation strategies.

Altria increased the size of its Board of Directors from eight to nine members to accommodate the appointment of Dr. Nabil Y. Sakkab and potentially to enhance the board's capacity for oversight and strategic decision-making, especially with the creation of an Innovation Committee.

The designation of Dr. Sakkab as an independent director means he meets the strict criteria set by the New York Stock Exchange and Altria's own standards, indicating he does not have significant financial or personal ties to the company that could compromise his objective judgment. This is crucial for effective corporate governance and for the Board's ability to act in the best interest of all shareholders.

The filing indicates the creation of a new 'Innovation Committee' of the Board of Directors. While the specific mandate isn't detailed in this 8-K, its creation alongside the appointment of a director with likely innovation expertise suggests Altria is prioritizing strategic development and future growth initiatives.